These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 15848720

  • 1. C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients.
    Barten MJ, Rahmel A, Garbade J, Richter M, Bittner HB, Dhein S, Mohr FW, Gummert JF.
    Transplant Proc; 2005 Mar; 37(2):1360-1. PubMed ID: 15848720
    [Abstract] [Full Text] [Related]

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients.
    Barten MJ, Rahmel A, Garbade J, Bold A, Bittner HB, Dhein S, Mohr FW, Gummert JF.
    Transplant Proc; 2005 Dec; 37(10):4532-4. PubMed ID: 16387162
    [Abstract] [Full Text] [Related]

  • 4. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I, Bigdeli AK, Vogeser M, Mueller T, Beiras-Fernandez A, Kaczmarek P, Schmoeckel M, Meiser B, Reichart B, Ueberfuhr P.
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [Abstract] [Full Text] [Related]

  • 5. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M, Millán O, Jiménez O, Campistol JM, Vidal E, Rojo I, Oppenheimer F, Fortuna V, Martorell J.
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [Abstract] [Full Text] [Related]

  • 6. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V, Giannetti N, Cecere R, Besner JG, Cantarovich M.
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [Abstract] [Full Text] [Related]

  • 7. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function.
    Barten MJ, Shipkova M, Bartsch P, Dhein S, Streit F, Tarnok A, Armstrong VW, Mohr FW, Oellerich M, Gummert JF.
    Ther Drug Monit; 2005 Apr; 27(2):123-31. PubMed ID: 15795640
    [Abstract] [Full Text] [Related]

  • 8. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.
    Gregoor PJ, de Sévaux RG, Hené RJ, Hesse CJ, Hilbrands LB, Vos P, van Gelder T, Hoitsma AJ, Weimar W.
    Transplantation; 1999 Nov 27; 68(10):1603-6. PubMed ID: 10589962
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A.
    Liver Transpl; 2003 Apr 27; 9(4):383-8. PubMed ID: 12682891
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.
    Ghio L, Ferraresso M, Viganò SM, Ginevri F, Perfumo F, Gianoglio B, Murer L, Zacchello G, Dello Strologo L, Cardillo M, Tirelli S, Valente U, Edefonti A.
    Transplant Proc; 2005 Mar 27; 37(2):856-8. PubMed ID: 15848555
    [Abstract] [Full Text] [Related]

  • 11. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection.
    Klupp J, van Gelder T, Dambrin C, Regieli JJ, Boeke K, Billingham ME, Morris RE.
    J Heart Lung Transplant; 2004 Mar 27; 23(3):334-51. PubMed ID: 15019644
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD.
    Liver Transpl; 2007 Nov 27; 13(11):1570-5. PubMed ID: 17969194
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics of T-cell function for monitoring immunosuppression.
    Barten MJ, Tarnok A, Garbade J, Bittner HB, Dhein S, Mohr FW, Gummert JF.
    Cell Prolif; 2007 Feb 27; 40(1):50-63. PubMed ID: 17227295
    [Abstract] [Full Text] [Related]

  • 14. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep 27; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
    Böhler T, Canivet C, Galvani S, Therville N, Salvayre R, Negre-Salvayre A, Durand D, Thomsen M, Rostaing L, Kamar N.
    Int Immunopharmacol; 2008 May 27; 8(5):769-73. PubMed ID: 18387521
    [Abstract] [Full Text] [Related]

  • 16. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts.
    Grinyó JM, Cruzado JM, Millán O, Caldés A, Sabaté I, Gil-Vernet S, Serón D, Brunet M, Campistol JM, Torras J, Martorell J.
    Transplantation; 2004 Nov 15; 78(9):1400-3. PubMed ID: 15548982
    [Abstract] [Full Text] [Related]

  • 17. The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.
    Gustafsson F, Barth D, Delgado DH, Nsouli M, Sheedy J, Ross HJ.
    Eur J Clin Pharmacol; 2009 Jul 15; 65(7):659-65. PubMed ID: 19458944
    [Abstract] [Full Text] [Related]

  • 18. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.
    Sheshgiri R, Gustafsson F, Sheedy J, Rao V, Ross HJ, Delgado DH.
    J Heart Lung Transplant; 2009 Nov 15; 28(11):1193-7. PubMed ID: 19783164
    [Abstract] [Full Text] [Related]

  • 19. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N.
    Liver Transpl; 2004 Apr 15; 10(4):492-502. PubMed ID: 15048791
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.
    Smak Gregoor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W.
    Nephrol Dial Transplant; 1999 Mar 15; 14(3):706-8. PubMed ID: 10193823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.